Single-Dose, Dose-Escalation Study With LY3303560 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2017
At a glance
- Drugs LY 3303560 (Primary) ; LY 3303560 (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly
- 02 Aug 2017 Planned number of patients changed from 90 to 110.
- 07 Jul 2017 Planned End Date changed from 1 May 2018 to 1 May 2019.
- 07 Jul 2017 Planned primary completion date changed from 1 May 2018 to 1 May 2019.